(Q53547209)

15 May 2018

title

Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. (English)

1 reference

15 May 2018

author name string

Saito AM

1

1 reference

15 May 2018

Zahrieh D

2

1 reference

15 May 2018

Cutler C

3

1 reference

15 May 2018

Ho VT

4

1 reference

15 May 2018

Antin JH

5

1 reference

15 May 2018

Soiffer RJ

6

1 reference

15 May 2018

Alyea EP

7

1 reference

15 May 2018

Lee SJ

8

1 reference

15 May 2018

language of work or name

English

0 references

publication date

11 June 2007

1 reference

15 May 2018

Bone Marrow Transplantation

published in

1 reference

15 May 2018

volume

40

1 reference

15 May 2018

issue

3

1 reference

15 May 2018

page(s)

209-217

1 reference

15 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705733

exact match

0 references

cites work

Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Low incidence of pulmonary complications following nonmyeloablative stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Nonmyeloablative allogeneic stem-cell transplantation for hematologic malignancies: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Decreased transfusion requirements for patients receiving nonmyeloablative compared with conventional peripheral blood stem cell transplants from HLA-identical siblings

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Haematopoietic stem cell transplantation with non-myeloablative conditioning in the outpatient setting: results, complications and admission requirements in a single institution.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Is it safe to treat allogeneic stem cell transplanted recipients at home during the pancytopenic phase? A pilot trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Allogeneic stem cell transplantation in the myelodysplastic syndromes: interim results of outcome following reduced-intensity conditioning compared with standard preparative regimens.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Estimating Physicians' Work for a Resource-Based Relative-Value Scale

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

The central role of the propensity score in observational studies for causal effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Individual Comparisons by Ranking Methods

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

A risk score for mortality after allogeneic hematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

The importance of reporting patient recruitment details in phase III trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705733

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705733

1 reference

15 May 2018

1 reference

15 May 2018